Alberto Castro

20 years ago over New Years, I founded WikiDoc.org , a free, copyleft, open access textbook of medicine. Thousands of doctors have edited it millions of times. It is viewed over a billion times per year. Send an email to alberto.castro@baiminstitute.org to become an editor and help keep our content up to date and earn academic credit !

Tirzepatide Lowers MACE vs Dulaglutide in SURPASS-CVOT Patients With Heart Failure Written by @acastrom91 Summary, analysis and more #AHA2025 coverage below! shorturl.at/aecLm @CMichaelGibson @ceciliabahit #Cardiology #HeartFailure #Medicine #diabetes #tirzepatide

Another @wikidoc meeting where the dissemination of medical knowledge and global collaboration come together to build a true academic community. Honored to be part of a project founded by my mentor Dr. @CMichaelGibson that continues to impact medical education worldwide #MedEd

Health360xai Successfully Implemented Decentralized Clinical Trials in Underserved Populations Written by @acastrom91! Summary, analysis and more #ACC25 coverage below! cardiologynownews.org/health360x-ai-… @CMichaelGibson @ceciliabahit

As co-founders of the Internal Medicine Interest Group (IMIG), we are proud to present a platform dedicated to discussion, engagement, and enrichment of those who wish to be part of it.

Improved Accuracy of HF Diagnosis with HFDetect-AI Written by @acastrom91! Summary, analysis and more #ESCCongress coverage below! cardiologynownews.org/improved-accur… @CMichaelGibson

Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI Written by @acastrom91! Summary, analysis and more #ESCCongress coverage below! cardiologynownews.org/pre-hospital-p… @CMichaelGibson

SWEDEGRAFT Trial: No Advantage of No-Touch vs Conventional Vein Harvesting in Coronary Artery Bypass Surgery Written by @acastrom91! Summary, analysis and more #ESCCongress coverage below! cardiologynownews.org/swedegraft-tri… @CMichaelGibson

#ACC24 #JACC LBCT SimPub: #AEGIS-II trial shows numerically lower rates of CV death & #cvMI, type-1 MI, & stent thrombosis-related MI compared to placebo suggesting a role of apoA-I in ⬇️ subsequent plaque disruption events via enhanced cholesterol efflux bit.ly/3PSxU9M

IVUS -DBC: IVUS-guided drug-coated balloon angioplasty improves primary patency Written by @acastrom91 ! Summary, analysis and more #ACC24 coverage below! cardiologynownews.org/ivus-dbc-ivus-… @CMichaelGibson

IVUS-Guided DES Reduced MACE at 1 year Compared to Angiography-Guided PCI: IVUS-ACS Trial Written by @acastrom91! Summary, analysis and more #ACC24 coverage below! cardiologynownews.org/ivus-guided-de… @CMichaelGibson

AEGIS-II trial shows in AMI pts with multivessel disease + additional CV risk factors and on GDMT, 4 weekly infusions of CSL112 did not reduce primary endpoint of CV death, MI, or stroke thru 90 days. Additional analysis shows CV outcome benefits statistically significant in pts with baseline high LDL > 100 mg/dl.

If your LDL is low & you don’t have a lot of lipid in your plaque then delipidation is not going to help. If you have high LDL, you have more lipid in your plaque and should have the garbage trucks take the garbage out, summarizes Dr. @CMichaelGibson on the AEGIS-II trial. #ACC24

In todays Wall Street Journal I talk about how new anticoagulant drugs called Factor XI inhibitors could reduce the higher risk of bleeding: “Too low of a dose, you clot; too high of a dose, you bleed. Our goal is to keep people from falling off the balance beam.” wsj.com/health/pharma/… via @WSJ

Recaticimab Effective as Add-On Therapy in Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia: REMAIN-2 Trial  Written by @acastrom91! Summary and analysis and more #AHA23 coverage below! cardiologynownews.org/recaticimab-ef… @CMichaelGibson

Lowering blood pressure significantly reduced dementia risk in people with hypertension in rural China Written by @acastrom91! Summary and analysis and more #AHA23 coverage below! cardiologynownews.org/lowering-blood… @CMichaelGibson

RIGHT trial: Routine post-procedural anticoagulation after primary PCI in STEMI fails to improve ischemic outcomes at 30 days #ESCCongress

DICTATE-AHF Trial: Early Dapagliflozin in AHF does not meet primary endpoint of diuretic efficiency Written by @acastrom91 Summary and analysis and more #ESCCongress coverage below! cardiologynownews.org/dictate-ahf-tr… @CMichaelGibson

RIGHT Trial: Anticoagulation shows no benefit after primary PCI in STEMI Written by @acastrom91 Summary and analysis and more #ESCCongress coverage below! cardiologynownews.org/right-trial-an… @CMichaelGibson

FIRE: Complete revascularization better than culprit-only strategy for elderly with MI and MVD Written by Alberto Castro! Summary and analysis and more #ESCCongress coverage below! cardiologynownews.org/fire-complete-… @CMichaelGibson